Abstract
Skyhawk Therapeutics, one of C&EN’s 10 Start-Ups to Watch in 2019, has raised $133 million to further develop small-molecule drugs that modify RNA expression. Skyhawk says it has raised more than $600 million to date and could earn more than $20 billion in milestone payments through collaborations with firms including Bristol Myers Squibb, Merck & Co., and Vertex Pharmaceuticals. The start-up is developing drugs for cancer and for autoimmune, neurodegenerative, neuromuscular, and viral diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
